Clinical Results

Restorex® for PD, 3 Month Data

A randomized, controlled clinical trial using the RestoreX device in men with Peyronie’s disease is taking place at Mayo Clinic. Updated clinical results were presented at the Annual Meeting of the Southeastern Section of the American Urological Association in March 2019.

The results are summarized below.

Study Design

The study randomly assigned 110 men to one of four treatment categories:

  1. No treatment (control)
  2. RestoreX 1, 30-minute treatment/day
  3. RestoreX 2, 30-minute treatments daily (total of 60 minutes)
  4. RestoreX 3, 30-minute treatments/day (90 minutes total).

The study was designed with a “control” group that did not use any therapy allowing for a direct comparison between RestoreX and the “no treatment” group. The study is one of only two randomized, controlled studies evaluating traction therapy in men with Peyronie’s disease. It will be the largest study ever conducted using traction therapy in men with PD and is the only randomized, controlled trial evaluating the use of traction for 2, 30-minute treatment sessions per day.  It is also the only study to incorporate an “intent to treat” analysis meaning results were presented for all men who entered the study, not just those doing the treatment perfectly.

The characteristics of the men in the active treatment groups were well matched to those of the men in the control group allowing for accurate comparisons of treatment success. Most notably, on average men had been diagnosed with PD for just under 4 years, the average primary curvature was 45 degrees and nearly two-thirds of the men in the trial had tried some PD treatment already.

Patient Characteristics

Variable RestoreX Control
Average Age (years) 58.5 58.1
Length to tip (cm) 14.8 14.8
Length to corona (cm) 11.4 11.8
Duration of PD (months) 46.0 51.8
Curvature Primary (degrees) 45.4 44.2
Curvature Composite (degrees) 59.7 58.3
Indentation, % of men 37 48.5
Prior Therapies, % of men 65.9 74.1

Study Results – improvement in curvature, length, and erectile function

The presentation at the Southeastern Section meeting reported on 63 men using RestoreX for 12 weeks of treatment. On average, 77% of men experienced improvements in curvature. Of those, the average improvement was 17-degrees, a 28% reduction from baseline. In contrast, the control group exhibited a 1-degree reduction or 2.4% improvement from their starting point. These results were statistically significant, meaning the results were likely due to RestoreX rather than chance alone.

Curvature after 12 weeks

RestoreX Control (no treatment)
Change in curvature (degrees) -17° -1°
Percent change in curvature compared to baseline -28% -2.4%

Of the nearly 80% or 4 in 5 men experiencing reduction in curvature, 50% achieved greater than a 20% reduction in curve.

Increases in penile length were also recorded. The results included a 1.6 cm gain or 11% in the 94% of men in the RestoreX group that showed improvement in length versus a 0.3 cm gain or 2.2% in the control group. All results were statistically significant.

Length after 12 weeks

RestoreX Control (no treatment)
Change in length (cm) +1.6 cm +0.3 cm
Percent change in length compared to baseline +11% +2.2%

Approximately 19 in 20 study participants experienced an improvement in length after just 12 weeks of treatment. Approximately 29% of men in the trial experienced greater than a 2.0cm increase in length.

RestoreX treatment for 12 weeks also improved men’s sexual function.  Average Erectile Function scores for men in the trial that had an overall IIEF score of less than 25 ( note some amount of Erectile Dysfunction ) increased by 4.3 points compared to men in the control group that saw a decline of 0.7. Additionally, men in the trial noted a 1.5-point improvement in intercourse satisfaction compared to a 0.4-point decline in the control group.

At the beginning of the trial 47% of men reported they were unable to have penetrative sex. After twelve weeks of treatment using the RestoreX device, 80% of these men, a total of 38% reported an improved ability to penetrate.

The study also tracked complications (adverse events).  These were determined at baseline and after 12 weeks of treatment with RestoreX.  All symptoms related to the use of RestoreX resolved within a few minutes of stopping a treatment. No men experienced any permanent new complications from the treatment and no men stopped using RestoreX as a result of the events listed below.

Tracked Complications

*All symptoms resolved within a few minutes of stopping a treatment.
Event 3 months
Discoloration (blue color) 35% of total, all resolved in < 5 min
Decreased penile sensation 57%, all resolved within 24 hours
Cold glans (head of penis) 0%
Minor penile discomfort 27%, all resolved in < 5 min
De-Novo curvature 0%

Results of the study revealed other interesting findings.

As shown below, 67% of men were very or somewhat satisfied with the RestoreX device, while 30% were neutral and just 3% somewhat dissatisfied (0% very dissatisfied)

After six months of use, nearly 90% of men in the trial who used traction indicated that traction with RestoreX would be their preferred therapy to treat PD if they were starting treatment for the first time. Please note men could indicate more than one treatment.

Notably, all men who had used another traction device prior to starting the clinical trial stated that RestoreX was either much better (89%) or somewhat better (11%) than the other traction device(s) they had previously used.

In summary, RestoreX is the only penile traction therapy device shown in a randomized controlled clinical trial to improve penile length and curvature in either 1, 2 or 3 30-minute treatment sessions per day for 12 weeks.  Other traction products required up to 8 hours of daily use. In addition, men who used RestoreX experience improvements in erectile function, overall, compared to those in the control group.  Finally, the results of the clinical trial demonstrated safety with only mild, temporary side effects with use.